| Identification | Back Directory | [Name]
JTE-013 | [CAS]
383150-41-2 | [Synonyms]
CS-2553
JTE-013;JTE 013;JTE013
1-(2,6-dichloro-4-pyridyl)-3-[(4-isopropyl-1,3-dimethyl-pyrazolo[3,4-b]pyridin-6-yl)amino]urea
1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea
1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(2,6-dichloro-4-pyridinyl)-semicarbazide
1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-dichloro-4-pyridinyl)-semicarbazide
N-(2,6-Dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]hydrazinecarboxamide
Hydrazinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- | [Molecular Formula]
C17H19Cl2N7O | [MDL Number]
MFCD09878275 | [MOL File]
383150-41-2.mol | [Molecular Weight]
408.29 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥20mg/mL | [form ]
powder | [pka]
9.32±0.43(Predicted) | [color ]
white to off-white | [InChI]
1S/C17H19Cl2N7O/c1-8(2)11-7-14(22-16-15(11)9(3)25-26(16)4)23-24-17(27)20-10-5-12(18)21-13(19)6-10/h5-8H,1-4H3,(H,22,23)(H2,20,21,24,27) | [InChIKey]
RNSLRQNDXRSASX-UHFFFAOYSA-N | [SMILES]
Clc1nc(cc(c1)NC(=O)NNc2nc3[n](nc(c3c(c2)C(C)C)C)C)Cl |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS06 | [Signal word ]
Danger | [Hazard statements ]
H301 | [Precautionary statements ]
P301+P310 | [Hazard Codes ]
T | [Risk Statements ]
25 | [Safety Statements ]
45 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
3 | [Storage Class]
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | [Hazard Classifications]
Acute Tox. 3 Oral |
| Hazard Information | Back Directory | [Description]
Sphingosine-1-phosphate (S1P) is a bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis. It exerts its activity by binding to five distinct G protein-coupled receptors, S1P1/EDG-1, S1P2/EDG-5, S1P3/EDG-3, S1P4/EDG-6, and S1P5/EDG-8. JTE-013 is a potent, selective sphingosine-1-phosphate 2 (S1P2) receptor antagonist that binds to the human and rat receptors with IC50 values of 17 and 22 nM, respectively, (IC50 values >10 μM for human S1P1 and S1P3). It reverses the inhibitory effects of S1P on cell migration of vascular endothelial cells and smooth muscle cells. Similarly, JTE-013 reverses the inhibition of S1P on invasion and migration of B16 melanoma cells. JTE-013 inhibits S1P-induced contraction of, as well as cyclic AMP accumulation in, coronary artery smooth muscle cells. | [Uses]
JTE-013 has been used in in vitro blood?brain barrier (BBB) and blood?tumor barrier (BTB) assays. | [Definition]
ChEBI: 1-(2,6-dichloro-4-pyridinyl)-3-[(1,3-dimethyl-4-propan-2-yl-6-pyrazolo[3,4-b]pyridinyl)amino]urea is a pyrazolopyridine. | [Biochem/physiol Actions]
JTE-013 can enhance the excitability of small-diameter sensory neurons. It has the ability to repress sphingosine 1-phosphate (S1P)-mediated cellular migration. | [storage]
Store at +4°C | [References]
[1] MELISSA R PITMAN. The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.[J]. Scientific Reports, 2022: 454. DOI: 10.1038/s41598-021-04009-w
[2] MAKOTO OSADA. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist[J]. Biochemical and biophysical research communications, 2002, 299 3: Pages 483-487. DOI: 10.1016/s0006-291x(02)02671-2
[3] KAYO ARIKAWA. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity.[J]. The Journal of Biological Chemistry, 2003, 278 35: 32841-32851. DOI: 10.1074/jbc.m305024200
[4] QIUMIN XU BMED . JTE-013 Alleviates Inflammatory Injury and Endothelial Dysfunction Induced by Sepsis In Vivo and In Vitro[J]. Journal of Surgical Research, 2021, 265: Pages 323-332. DOI: 10.1016/j.jss.2021.03.006
[5] MENGDIE WANG. Inhibition of sphingosine 1-phosphate (S1P) receptor 1/2/3 ameliorates biological dysfunction in rheumatoid arthritis fibroblast-like synoviocyte MH7A cells through Gαi/Gαs rebalancing[J]. Clinical and Experimental Pharmacology and Physiology, 2021, 48 8: 1080-1089. DOI: 10.1111/1440-1681.13460
[6] STEPHANIE S DUSABAN. Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes.[J]. Journal of Neuroinflammation, 2017: 111. DOI: 10.1186/s12974-017-0882-x
[7] NADINE AL ALAM Sawsan I K. FTY720P inhibits hepatic Na(+)-K(+) ATPase via S1PR2 and PGE2.[J]. Biochemistry and Cell Biology, 2016, 94 4: 371-377. DOI: 10.1139/bcb-2016-0025 |
|
| Company Name: |
Sigma-Aldrich
|
| Telephone: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Lynnchem
|
| Telephone: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
|